| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology, Vol 130, 1380-1386, Copyright © 1992 by Endocrine Society
ARTICLES |
C Clapp and RI Weiner
Reproductive Endocrinology Center, University of California, San Francisco 94143.
A 16-kilodalton N-terminal fragment of PRL (16K PRL) is formed by enzymatic cleavage of intact 23-kilodalton PRL (23K PRL) in the pituitary gland and in target tissues for PRL. 16K PRL inhibits the growth of capillary endothelial cells, while intact PRL was inactive suggesting that 16K PRL acted via a receptor other than the PRL receptor. To analyze whether this inhibitory effect could be mediated through an specific 16K PRL receptor, we characterized the binding of 16K PRL to membrane preparations of bovine brain capillary endothelial (BBE) cells. 16K PRL was generated by the proteolysis of rat 23K PRL with a particulate fraction from rat mammary gland homogenates and purified by gel filtration. The specific binding of [125I]16K PRL to BBE cell membranes was high affinity (Kd = 9.9 nM), saturable (Bmax = 4.8 pmol/mg protein), and reversible. In competition studies for [125I]16K PRL binding, 16K PRL was most potent, while little displacement was observed with high concentrations of 23K PRLs, growth hormones, and basic fibroblast growth factor. Blockade of reformation of disulfide bonds by carbamidomethylation of 16K PRL, a procedure which increases the biological activity of the molecule, increased its binding affinity (Kd = 0.9 nM). Cross-linking experiments identified a 52,000 and a 32,000 mol wt protein as the major 16K PRL binding species. These data demonstrate the presence of specific, high affinity, saturable binding sites for 16K PRL on BBE cell membranes and support biological findings that 16K PRL inhibits capillary endothelial cell proliferation, through a novel, high affinity receptor.
This article has been cited by other articles:
 |
|
 |
|
  M. E. Cruz-Soto, G. Cosio, M. C. Jeziorski, V. Vargas-Barroso, M. B. Aguilar, A. Carabez, P. Berger, P. Saftig, E. Arnold, S. Thebault, et al. Cathepsin D Is the Primary Protease for the Generation of Adenohypophyseal Vasoinhibins: Cleavage Occurs within the Prolactin Secretory Granules Endocrinology, December 1, 2009; 150(12): 5446 - 5454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Clapp, S. Thebault, M. C. Jeziorski, and G. Martinez De La Escalera Peptide Hormone Regulation of Angiogenesis Physiol Rev, October 1, 2009; 89(4): 1177 - 1215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Clapp, S. Thebault, E. Arnold, C. Garcia, J. C. Rivera, and G. M. de la Escalera Vasoinhibins: novel inhibitors of ocular angiogenesis Am J Physiol Endocrinol Metab, October 1, 2008; 295(4): E772 - E778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ben-Jonathan, C. R. LaPensee, and E. W. LaPensee What Can We Learn from Rodents about Prolactin in Humans? Endocr. Rev., February 1, 2008; 29(1): 1 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-H. Lee, J. Kunz, S.-H. Lin, and L.-y. Yu-Lee 16-kDa Prolactin Inhibits Endothelial Cell Migration by Down-Regulating the Ras-Tiam1-Rac1-Pak1 Signaling Pathway Cancer Res., November 15, 2007; 67(22): 11045 - 11053. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Tabruyn, C. Sabatel, N.-Q.-N. Nguyen, C. Verhaeghe, K. Castermans, L. Malvaux, A. W. Griffioen, J. A. Martial, and I. Struman The Angiostatic 16K Human Prolactin Overcomes Endothelial Cell Anergy and Promotes Leukocyte Infiltration via Nuclear Factor-{kappa}B Activation Mol. Endocrinol., June 1, 2007; 21(6): 1422 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N.-Q.-N. Nguyen, S. P. Tabruyn, L. Lins, M. Lion, A. M. Cornet, F. Lair, F. Rentier-Delrue, R. Brasseur, J. A. Martial, and I. Struman Prolactin/growth hormone-derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis PNAS, September 26, 2006; 103(39): 14319 - 14324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Macotela, M. B. Aguilar, J. Guzman-Morales, J. C. Rivera, C. Zermeno, F. Lopez-Barrera, G. Nava, C. Lavalle, G. M. de la Escalera, and C. Clapp Matrix metalloproteases from chondrocytes generate an antiangiogenic 16 kDa prolactin J. Cell Sci., May 1, 2006; 119(9): 1790 - 1800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ueda, U. Ozerdem, Y.-H. Chen, M. Yao, K. T. Huang, H. Sun, M. Martins-Green, P. Bartolini, and A. M Walker A molecular mimic demonstrates that phosphorylated human prolactin is a potent anti-angiogenic hormone. Endocr. Relat. Cancer, March 1, 2006; 13(1): 95 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-h. Lee, M. Nishino, T. Mazumdar, G. E. Garcia, M. Galfione, F. L. Lee, C. L. Lee, A. Liang, J. Kim, L. Feng, et al. 16-kDa Prolactin Down-Regulates Inducible Nitric Oxide Synthase Expression through Inhibition of the Signal Transducer and Activator of Transcription 1/IFN Regulatory Factor-1 Pathway Cancer Res., September 1, 2005; 65(17): 7984 - 7992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Tabruyn, N.-Q.-N. Nguyen, A. M. Cornet, J. A. Martial, and I. Struman The Antiangiogenic Factor, 16-kDa Human Prolactin, Induces Endothelial Cell Cycle Arrest by Acting at Both the G0-G1 and the G2-M Phases Mol. Endocrinol., July 1, 2005; 19(7): 1932 - 1942. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gonzalez, A. M. Corbacho, J. P. Eiserich, C. Garcia, F. Lopez-Barrera, V. Morales-Tlalpan, A. Barajas-Espinosa, M. Diaz-Munoz, R. Rubio, S.-H. Lin, et al. 16K-Prolactin Inhibits Activation of Endothelial Nitric Oxide Synthase, Intracellular Calcium Mobilization, and Endothelium-Dependent Vasorelaxation Endocrinology, December 1, 2004; 145(12): 5714 - 5722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Piwnica, P. Touraine, I. Struman, S. Tabruyn, G. Bolbach, C. Clapp, J. A. Martial, P. A. Kelly, and V. Goffin Cathepsin D Processes Human Prolactin into Multiple 16K-Like N-Terminal Fragments: Study of Their Antiangiogenic Properties and Physiological Relevance Mol. Endocrinol., October 1, 2004; 18(10): 2522 - 2542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. E. Turner, A. L. Harris, S. Melmed, and J. A. H. Wass Angiogenesis in Endocrine Tumors Endocr. Rev., October 1, 2003; 24(5): 600 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Tabruyn, C. M. Sorlet, F. Rentier-Delrue, V. Bours, R. I. Weiner, J. A. Martial, and I. Struman The Antiangiogenic Factor 16K Human Prolactin Induces Caspase-Dependent Apoptosis by a Mechanism that Requires Activation of Nuclear Factor-{kappa}B Mol. Endocrinol., September 1, 2003; 17(9): 1815 - 1823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. V. Clevenger, P. A. Furth, S. E. Hankinson, and L. A. Schuler The Role of Prolactin in Mammary Carcinoma Endocr. Rev., February 1, 2003; 24(1): 1 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kim, W. Luo, D.-T. Chen, K. Earley, J. Tunstead, L.-Y. Yu-Lee, and S.-H. Lin Antitumor Activity of the 16-kDa Prolactin Fragment in Prostate Cancer Cancer Res., January 15, 2003; 63(2): 386 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Bentzien, I. Struman, J.-F. Martini, J. Martial, and R. Weiner Expression of the Antiangiogenic Factor 16K hPRL in Human HCT116 Colon Cancer Cells Inhibits Tumor Growth in Rag1-/- Mice Cancer Res., October 1, 2001; 61(19): 7356 - 7362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ochoa, P. Montes de Oca, J. C. Rivera, Z. Duenas, G. Nava, G. M. de la Escalera, and C. Clapp Expression of Prolactin Gene and Secretion of Prolactin by Rat Retinal Capillary Endothelial Cells Invest. Ophthalmol. Vis. Sci., June 1, 2001; 42(7): 1639 - 1645. [Abstract] [Full Text]
|
|
|
|
|
|
J.-F. Martini, C. Piot, L. M. Humeau, I. Struman, J. A. Martial, and R. I. Weiner The Antiangiogenic Factor 16K PRL Induces Programmed Cell Death in Endothelial Cells by Caspase Activation Mol. Endocrinol., October 1, 2000; 14(10): 1536 - 1549. [Abstract] [Full Text]
|
|
|
|
|
|
Z. Duenas, L. Torner, A. M. Corbacho, A. Ochoa, G. Gutierrez-Ospina, F. Lopez-Barrera, F. A. Barrios, P. Berger, Gonzalo Martinez de la Escalera, and C. Carmen Inhibition of Rat Corneal Angiogenesis by 16-kDa Prolactin and by Endogenous Prolactin-like Molecules Invest. Ophthalmol. Vis. Sci., October 1, 1999; 40(11): 2498 - 2505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D'Angelo, J.-F. Martini, T. Iiri, W. J. Fantl, J. Martial, and R. I. Weiner 16K Human Prolactin Inhibits Vascular Endothelial Growth Factor-Induced Activation of Ras in Capillary Endothelial Cells Mol. Endocrinol., May 1, 1999; 13(5): 692 - 704. [Abstract] [Full Text]
|
|
|
|
|
|
I. Struman, F. Bentzien, H. Lee, V. Mainfroid, G. D'Angelo, V. Goffin, R. I. Weiner, and J. A. Martial Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: An efficient mechanism for the regulation of angiogenesis PNAS, February 16, 1999; 96(4): 1246 - 1251. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Boguszewski, P.-A. Svensson, T. Jansson, R. Clark, L. M. S. Carlsson, and B. Carlsson Cloning of Two Novel Growth Hormone Transcripts Expressed in Human Placenta J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2878 - 2885. [Abstract] [Full Text]
|
|
|
|
 |
|
 I Krause, Z Blumenfeld, M Malchinsky, S Cohen, M Blank, A Eldor, B Weksler, K Schweitzer, and Y Shoenfeld Anti-endothelial cell antibodies in the sera of hyperprolactinemic women Lupus, July 1, 1998; 7(6): 377 - 382. [Abstract] [PDF]
|
|
|
|
 |
|
 D Jackson, O. Volpert, N Bouck, and D. Linzer Stimulation and inhibition of angiogenesis by placental proliferin and proliferin-related protein Science, December 2, 1994; 266(5190): 1581 - 1584. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
